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Human immunodeficiency virus (HIV) particles produced in COS-7 cells transfected with HIV type 1
(HIV-i) proviral DNA contain 8 molecules of tRNA3LY' per 2 molecules of genomic RNA and 12 molecules of
tRNALys per 2 molecules of genomic RNA. When COS-7 cells are transfected with a plasmid containing both
HIV-1 proviral DNA and a human tRNA3LYS gene, there is a large increase in the amount of cytoplasmic
tRNA3LYS per microgram of total cellular RNA, and the tRNA3LYS content in the virus increases from 8 to 17
molecules per 2 molecules of genomic RNA. However, the total number of tRNALYS molecules per 2 molecules
of genomic RNA remains constant at 20; i.e., the viral tRNAliS content decreases from 12 to 3 molecules per
2 molecules of genomic RNA. All detectable tRNA3YS is aminoacylated in the cytoplasm of infected cells and
deacylated in the virus. When COS-7 cells are transfected with a plasmid containing both HlV-1 proviral DNA
and a mutant amber suppressor tRNA3YS gene (in which the anticodon is changed from TTT to CTA), there is
also a large increase in the relative concentration of cytoplasmic tRNALYS, and the tRNALYS content in the virus
increases from 8 to 15 molecules per 2 molecules of genomic RNA, with a decrease in viral tRNALYS from 12
to 5 molecules per 2 molecules of genomic RNA. Thus, the total number of molecules of tRNALYS in the virion
remains at 20. The alteration of the anticodon has little effect on the viral packaging of this mutant tRNA in
spite of the fact that it no longer contains the modified base mcm 5s2U at position 34, and its ability to be
aminoacylated is significantly impaired compared with that of wild-type tRNALYS. Viral particles which have
incorporated either excess wild-type tRNALYS or mutant suppressor tRNALYS show no differences in viral
infectivity compared with wild-type HIV-1.
During retroviral assembly, a limited number of host cell
tRNAs are selected for incorporation into the virus (33). One
of these, termed the primer tRNA, is placed onto the primer-
binding site of the viral genome, where it serves as a primer for
the reverse transcriptase (RT)-catalyzed synthesis of minus-
strand cDNA. The tRNAs most commonly used as primer
tRNAs are tRNAT1P in avian retroviruses (7, 10, 22, 27, 34) and
tRNAPro (9, 20, 28) and tRNALYS (21, 32) in mammalian
retroviruses. In human immunodeficiency virus type 1 (HIV-
1), the primer tRNA appears to be tRNA3YS (24), one of three
major tRNALYS isoacceptors found in mammalian cells (23).
During the assembly of HIV, the major tRNALYS isoaccep-
tors, tRNALys and tRNALYS, are selectively incorporated into
the virus (14). This select packaging occurs independently of
genomic RNA encapsidation (17, 19, 22), and evidence impli-
cating Pr1609'9aPo as being the likely viral precursor protein
which carries the tRNALYS into the virus has been reported
(19). In vitro studies of the interaction between mature p66/
p51 RT and tRNALYS indicate that the anticodon arm of the
tRNA is involved in this interaction (1, 2, 26, 36). However,
little is known about the signals on tRNA3YS which cause it to
be chosen for viral incorporation from over 100 other cellular
tRNAs and subsequently to be placed onto the primer-
binding site of the viral genomic RNA, where it functions as
the primer for HIV-1 RT. In the absence of purified func-
* Corresponding author. Mailing address: Lady Davis Institute for
Medical Research, Jewish General Hospital, 3755 Cote Ste-Catherine
Rd., Montreal, Quebec, Canada H3T 1E2. Phone: (514) 340-8260.
Fax: (514) 340-7502.
tional Pr1609'9aPo, the determination of the packaging sig-
nals on tRNALYs must be by an in vivo approach.
Transfection of COS-7 cells with HIV-1 proviral DNA
results in the production of infectious HIV-1 particles showing
select incorporation of tRNALYS (14). In this work, we have
investigated whether a wild-type or mutant form of the
tRNALYS gene can be introduced into these cells along with
HIV-1 proviral DNA and produce wild-type or mutant
tRNALYS which will be packaged into the virus. We find that
exogenous tRNALYS will be packaged into the virus, changing
the tRNA3YS/tRNA1LY ratio, but that the total amount of
tRNALYS packaged into a virus remains at 20 molecules per 2
molecules of genomic RNA.
Possible signals on tRNALYS which target it for interaction
with the M609a9P° precursor could include a specific base
sequence or base modification, the state of aminoacylation of
the tRNA, or cytoplasmic proteins which complex with the
tRNA, such as lysine tRNALYS synthetase. In this work, we
initiate studies on the first two parameters. COS-7 cells were
transfected with a plasmid containing either the HIV-1 provi-
ral DNA alone or the HIV-1 proviral DNA combined with
either a wild-type tRNA3YS gene or an amber suppressor
tRNA3YS gene in which the anticodon has been changed from
TTl' to CTA (11, 12). We then demonstrated the ability of the
excess wild-type or mutant tRNA3YS transiently produced from
these plasmids to be incorporated into HIV-1. The packaging
of the tRNALYs appears to be insensitive to alterations in the
anticodon loop which remove both the thiolated U (mcm5s2U)
and U at position 34 or 36 in the anticodon and which reduce
the ability of this tRNA to be aminoacylated.
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MATERIALS AND METHODS
Plasmid construction. SVC21.BH10 is a simian virus 40-
based vector which contains wild-type HIV-1 proviral DNA
(29) and was a gift of E. Cohen, University of Montreal.
pMV104-Lys and pMV104-Lys (Su') are plasmids containing,
respectively, a human tRNALYS gene and an amber suppressor
tRNA3YS gene (anticodon T1lT changed to CTA). Both plas-
mids were a gift from Ye Shih Ho, Wayne State University (11,
12). SVC21.BHlOLys3 and SVC21.BH10Su+ contain the
HIV-1 proviral DNA plus either the wild-type tRNA3ys gene
or the amber suppressor tRNA3YS gene, respectively. Both
plasmids were constructed by removing a BamHI-EcoRI frag-
ment from the pMV104 plasmids and cloning this fragment
into the HpaI site of SVC21.BH10, which is upstream of the
HIV-1 proviral DNA sequence. Correct insertions were ana-
lyzed by using SpeI and NarI digestion and DNA sequencing.
Restriction enzymes were used according to the specifications
of the manufacturer.
Production of wild-type and mutant HIV-1 virus. Transfec-
tion of COS-7 cells with the above-described plasmids by the
calcium phosphate method was as previously described (15).
Virus was isolated from the cell culture medium at 63 h
posttransfection. The supernatant was first centrifuged in a
Beckman GS-6R rotor at 3,000 rpm for 30 min, and the virus
was then pelleted from the resulting supernatant by centrifu-
gation in a Beckman Ti45 rotor at 35,000 rpm for 1 h. The viral
pellet was then purified by centrifugation at 26,500 rpm for 1 h
through 15% sucrose onto a 65% sucrose cushion, using a
Beckman SW41 rotor.
Isolation of COS-7 cellular and viral RNAs and human
placental tRNALY'. Total cellular and viral RNAs were ex-
tracted from viral pellets by the guanidinium isothiocyanate
procedure (5). The purification of tRNA3'YS from human
placenta was performed as previously described (10). The
tRNA species designated 1, 2, and 3 on two-dimensional
polyacrylamide gel electrophoresis (2D-PAGE) gels have been
previously identified as two species of tRNA'ys and one species
of tRNA3ys, respectively (14). The term tRNA'ys refers to a
population of two tRNALYS species which differ by 1 bp in the
anticodon stem (23). In this paper, 2D-PAGE spots 1 and 2 are
collectively referred to as tRNA'Y' since we have not charac-
terized these two species sufficiently to distinguish tRNALYS
from tRNA2LYS (14).
RNA labeling. The fractionated RNA samples were labeled
by using the [32P]pCp 3' end-labeling technique (4). [32P]pCp
was made as follows. First, 5 mCi of [.y-32P]ATP (specific ac-
tivity, 3,000 Ci/mmol; Dupont, Canada) was dried in a micro-
centrifuge tube with N2. One hundred microliters of reaction
solution (50 mM Tris-HCl [pH 9.2], 5 mM MgCl2, 3 mM
dithiothreitol, 5% bovine serum albumin [BSA], 1 ,uM 3'-
CMP, and 10 U of T4 kinase) was added. The reaction mixture
was incubated at 37°C for 3 h, and the conversion of 3'-CMP
to [32P]pCp was monitored by polyethyleneimine thin-layer
chromatography in 0.8 M NH2SO4, which separates [32P]pCp
from [32p]ATp.
Labeling of the RNA with [32P]pCp was as previously
described (4, 16). After labeling, free [3 P]pCp was removed
from the labeled macromolecules either by using G-50 Seph-
adex (Pharmacia) homemade spin columns equilibrated with
TE buffer (10 mM Tris [pH 7.5], 1 mM EDTA) or during the
electrophoresis run. Before analysis by PAGE, the samples
were heated at 90°C for 2 min.
ID- and 2D-PAGE. Electrophoresis of viral RNA was car-
ried out at 4°C with the Hoeffer SE620 gel electrophoresis
apparatus. The gel size was 14 by 32 cm. The first dimension
was run in a 10% polyacrylamide-7 M urea gel for approxi-
mately 16 h at 800 V, until the bromphenol blue dye was
beginning to elute from the bottom of the gel. After autora-
diography, the piece of gel containing RNA was cut out,
embedded in a second gel (20% polyacrylamide, 7 M urea),
and run for 30 h (25 Watt limiting); this was followed by
autoradiography. All electrophoretic runs were carried out in
0.5 x TBE (1 x TBE is 50 mM Tris, 5 mM boric acid, and 1 mM
EDTA-Na2). The electrophoretic gel patterns shown in this
paper show only low-molecular-weight RNA, since the high-
molecular-weight viral genomic RNA cannot enter the poly-
acrylamide gels. Furthermore, these patterns represent only
the most abundant tRNA species present, since the high
specific activities of the labeled tRNAs used will reveal more
minor-abundance species with longer film exposures.
The signal intensity of each radioactive low-molecular-
weight RNA species in the 2D-PAGE RNA pattern was
determined by Phosphor-imaging (Bio-Rad, Toronto, Cana-
da).
Measurement of wild-type and mutant tRNA3YS by RNA-
DNA hybridization. To measure the amount of tRNA'YS (wild
type and mutant) present in cellular or viral RNA, we have
synthesized an 18-mer DNA oligonucleotide complementary
to the 3' 18 nucleotides of tRNA3Ys (5'TGGCGCCCGAA
CAGGGAC3'). This probe hybridizes specifically with both
wild-type and mutant tRNALYS (14) and was hybridized to
dot blots on Hybond N (Amersham) containing known
amounts of purified human placental tRNALYs and either
cellular tRNA or viral RNA produced in cells transfected
with either SVC21.BH10, SVC21.BH1OLys3, or SVC21.BH
10Su+. The DNA oligomer was first 5' end labeled by using
T4 polynucleotide kinase and [-y-32P]ATP (3,000 Ci/mmol;
Dupont Canada), and specific activities of 108 to 109 cpm/,ug
were generally reached. Approximately 107 cpm of oligomer
was generally used per blot in hybridization reactions.
DNA probes complementary to the anticodon arms of both
wild-type tRNA3Ys (5'CCCTCAGATTAAAAGTCTGAT
GC3') and amber suppressor tRNA3YS (5'CCCTCAGATTlA
GAGTCTGATGC3') were also synthesized. In order to spe-
cifically detect the presence of suppressor tRNA3-Ys in RNA
samples, blots were probed with 3 P-labeled anticodon probe
to the suppressor tRNALYS in the presence of an 8- to 25-fold
excess of nonradioactive oligonucleotide complementary to the
wild-type tRNA3ys anticodon arm.
Measurement of viral genomic RNA by quantitative PCR.
(i) Labeling of primer. One nanomole of sense primer was
mixed with 50 ,Ci of [_y-32P]ATP (Dupont) and end labeled
with 3 pAl of T4 polynucleotide kinase (10 U/pA; Pharmacia) in
kinase buffer (70 mM Tris-HCl [pH 7.5], 100 mM MgCl2, and
50 mM dithiothreitol) at 37°C for 1 h. Free radioactive label
was removed by passage through a G-25 spin column.
(ii) Reverse transcription. Ten picomoles of cold antisense
primer was mixed with a known volume of viral RNA or in
vitro-transcribed RNA in a total volume of 16.5 pA. Three
drops of oil layer was placed on top of the primer-template mix
to avoid evaporation. Tubes containing primer-template mix
were heated at 85°C for 3 min and slowly cooled down to room
temperature to allow primer-template annealing, and then 8.5
pl of RT master mix (30 mM Tris-HCl [pH 8.3], 5 mM MgCl2,
6 mM dithiothreitol, 1.5 puM deoxynucleoside triphosphates
[dNTPs], 0.5 jig of BSA, 10 U of RNase inhibitor [Promega],
and 5 U of Moloney murine leukemia virus RT [Pharmacia])
was added to the primer-template mix. Reaction tubes were
incubated at 37°C for 1 h. RT activity was terminated by
incubation at 95°C for 5 min.
(iii) PCR Seventy-five microliters of PCR master mix (10 pA
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FIG. 1. Two-dimensional PAGE patterns of cellular and viral tRNAs. Electrophoretic conditions are as described in the text. (A to C) Cellular
tRNA. (D to F) viral tRNA. (A and D) tRNA extracted from COS cells transfected with SVC21.BH10 (A) and from the HIV released from these
cells into the medium (D). (B and E) tRNA extracted from COS cells transfected with SVC21.BH1OLys3 (B) and from the HIV released from
these cells into the medium (E). (C and F) tRNA extracted from COS cells transfected with SVC21.BHlOSu+ (C) and from the HIV released from
these cells into the medium (F). Spots 1 and 2 are collectively referred to as tRNAlLs, spot 3 is referred to as tRNA3YS. These tRNA species have
been identified previously (8).
of lOx Taq DNA polymerase buffer [BRL/GIBCO], 10 ,ul of 2
mM dNTPs, 1 RI of 3 P-labeled primer mix, and 1.25 U of Taq
DNA polymerase [BRL/GIBCO]) was added to the reaction
tubes containing reverse transcription products, which were
incubated at 95°C. Reaction tubes were subjected to 19 cycles
of amplification (denaturation at 94°C for 1 min, annealing at
60°C for 1 min, and elongation at 72°C for 3 min). Aliquots of
PCR products were run on an 8% polyacrylamide gel with 7 M
urea to separate amplification products from excess radioac-
tive primers. The gel was dried at 80°C for 2 h and then
exposed to a Phosphor-imaging screen for quantitative mea-
surement on a Phosphor-imager.
(iv) Quantitative determination of genomic RNA in wild-
type and mutant viral RNA samples. Sense primer (JS1)
(5'AT-FCGGTTAAGGCCAGGGGG3') and antisense primer
(JA1) (5'GGGATGGITGTAGCTGTCCC3') were used for
PCR amplification. A 148-bp fragment, corresponding to
HIVIIIB DNA positions 843 to 990, was amplified.
A standard curve was established by using known amounts of
in vitro-transcribed RNA for RT-PCR. A 957-base RNA
fragment (sense) was made from a linearized DNA plasmid,
pEA2, with T7 RNA polymerase (pEA2 plasmid was a kind
gift from E. J. Arts of the McGill AIDS Centre). This RNA
fragment corresponds to HIVIIIB DNA sequence positions 473
to 1420.
Quantitation of genomic RNA in virus containing wild-type
and mutant tRNA3YS and of in vitro transcript RNA was done
by Phosphor-imaging (Bio-Rad). The relative intensities of
amplified signals were used to determine the concentration of
genomic RNA in the viral samples by using the standard curve.
Measurement of in vivo aminoacylation. In vivo aminoacy-
lation of tRNALYS was measured by techniques previously
described (11, 12, 31). To measure the extent of in vivo
aminoacylation of tRNA'-YS, the isolation of cellular or viral
RNA was performed under low-pH conditions required for
stabilizing the aminoacyl-tRNA bond. The guanadinium thio-
cyanate procedure for isolating RNA (5) was modified by
including 0.2 M sodium acetate (pH 4.0) in solution D, and the
J. VIROL.
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TABLE 1. Viral and cytoplasmic concentrations of tRNALYS
ng of Molecules of Molecules of Molecules of Molecules of Molecules of
tRNA,Lys per genomic tRNALys tRNA3LYS per tRNA3LYsAR/tNALL tRNAlLT per tRNAL)s per
RNA source ,ug of RNA (109) (1010) per ,u1 2 molecules ratio inv ru3 2 molecules 2 molecules
cellular per ,ul of of sampleb of genomic of genomic of genomictRNA sample' RNA RNAd RNA
SVC21.BH10 1.99 6.04 2.36 8 0.68 12 20
SVC21.BH10Lys3 5.96 8.06 6.79 17 6.02 3 20
SVC21.BH10Su+ 5.93 5.58 4.18 15 2.94 5 20
a A molecular mass of 324,868 g/mol for the 957-base genomic RNA standard was used in converting nanograms of genomic RNA standard to molecules of genomic
RNA.
b A molecular mass of 25,460 g/mol for the tRNA3LYs standard was used in converting nanograms of tRNA3LYS standard to molecules of tRNA3LYS.
c Determined by Phorphor-image analysis of the viral 2D-PAGE patterns shown in Fig. 1.
d The number of molecules of tRNAL was determined from the tRNALYVtRNA1LI2 ratios.
phenol used was equilibrated in 0.1 M sodium acetate (pH
5.0). The final isopropanol-precipitated RNA pellet was dis-
solved in 10 mM sodium acetate (pH 5.0) and stored at -70°C
until electrophoretic analysis. RNA was mixed with 1 volume
of loading buffer (0.1 M sodium acetate [pH 5.0], 8 M urea,
0.05% bromphenol blue, and 0.05% xylene cyanol) and elec-
trophoresed in a 0.5-mm-thick polyacrylamide gel containing 8
M urea in 0.1 M sodium acetate (pH 5.0). The running buffer
was 0.1 M sodium acetate (pH 5.0), and electrophoresis was
carried out at 300 V and 4°C for 15 to 18 h in a Hoefer SE620
electrophoresis apparatus. RNA was electroblotted onto a
Hybond N filter paper (Amersham) with an electrophoretic
transfer cell (Bio-Rad) at 750 mA for 15 min, using lx TBE.
Hybridization of the blots with probes for wild-type and
mutant tRNALYS was performed as described above. Deacy-
lated tRNA was produced by treating the RNA sample with 0.1
M Tris-HCl (pH 9.0) at 37°C for 3 h to hydrolyze the aminoacyl
linkage and provide an uncharged electrophoretic marker.
Infectivity assay. The cell culture supematant containing the
virus produced by transfected COS-7 cells was centrifuged in a
Beckman GS centrifuge at 3,000 rpm for 30 min, and the virus
was then pelleted by centrifugation in a Beckman Ti45 rotor at
35,000 rpm for 1 h and resuspended in RPMI 1640 medium
(GIBCO Laboratories). The different viral suspensions were
adjusted to equal amounts of p24 per milliliter by using the
commercial kit available for p24 antigen capture (Abbott
Laboratories). MT-4 cells (5 x 105) were incubated with 1 ml
of virus in RPMI 1640 medium, and after 3 h of incubation at
37°C, the cells were washed twice to remove excess virus and
then maintained in medium at a cell density of 3 x 105 per ml.
Culture fluids were replaced at day 4 after infection. The
supernatant was centrifuged in a Beckman GS centrifuge at
3,000 rpm for 30 min and stored at -70°C. The extent of
infection was assessed by RT assays (3, 25).
respectively, in HIV-1 produced from cells transfected with the
wild-type or mutant tRNA'YS gene.
The amounts of tRNA3YS found in the cytoplasm and in the
virus were determined by experiments profiled in Fig. 2 and 3.
For Fig. 2, panel I, known amounts of cytoplasmic RNA, viral
RNA, and purified tRNALYS were blotted onto Hybond N filter
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RESULTS
Figure 1 shows the 2D-PAGE pattern of cytoplasmic (A to
C) and viral (D to F) tRNAs produced in COS-7 cells
transfected with a plasmid containing either HIV-1 proviral
DNA alone (A and D) or both the HIV-1 gene and either a
wild-type (B and E) or a suppressor (C and F) tRNALYS gene.
Spots 1 and 2 both represent tRNA1LY, while spot 3 is tRNALYS
(14). It can be seen in Fig. 1 that the cellular and viral
tRNA3Ys/RNA13 ratios increase when cells are transfected
with either the wild-type or mutant tRNA3LYS gene. The signal
intensities of the viral tRNALYS spots were determined by
Phosphor-imaging, and the viral tRNA Ys/tRNAiY ratios are
listed in Table 1. These ratios increase nine- and fourfold,
Lys3
tRNA (ng)
FIG. 2. (I) Quantitation of tRNA3js in cellular and viral RNAs.
The specificity of a tRNALYs DNA oligomer probe has been described
previously (8). Various amount of purified human placenta tRNA3YS
were used as an external standard (top row). One-microgram samples
of cellular RNA and 1-,ul aliquots of the same viral RNA samples used
to quantitate genomic RNA in Fig. 3 were used to determine the
amount of tRNA3LY' present. The RNA samples are given the same
letter designation as in Fig. 1. (II) tRNA3L3" standard curve. Hybrid-
ization signals of purified human tRNA3LYS were used to construct a
standard curve. Concentrations of tRNA3Ys in the cellular and viral
RNA samples were calculated from this curve, and these values, or
values derived from them, are listed in Table 1.
VOL. 68, 1994
7680 HUANG ET AL.
Molecules of Standard RNA (106 )
*u4.1
*
....
50007
Ir 40X)
> /
(n
-
CD 2000 (
(1) 100 0 0-
RNA Molecules(x 10 6 )
FIG. 3. (Top) Quantitative RT-PCR. RT and I
on in vitro-transcribed genomic RNA (used as an e
on 0.1-,u aliquots of the same viral RNA samp]
tRNA3YS concentrations in Fig. 2. Amplified prod
8% polyacrylamide-7 M urea gel to separate amp
excess radioactive primers. (Bottom) Genomic I
dard curve. The relative intensities of amplifi
vitro-transcribed RNA were used to plot a standai
tions of genomic RNA from the viral RNA saml
from this curve, and the values are listed in Tabl(
paper and hybridized with a tRNA'Ys-spe
complementary to the 3'-terminal 18 nucle(
(14). The letters correspond to those in Fig.
amounts of cellular tRNA blotted (A, B, a]
mined by measuring the A260 of the samr
amounts of viral genomic RNA in the blotte(
E, and F) were determined by RT-PCR, a
The DNA probe hybridizes to the 3' end of I
not distinguish between wild-type and sup
From the tRNA"YS standard curve, we deter
concentrations of tRNA3'YS in the cytoplasm
and in the virus produced from these cells,
are listed in Table 1.
In cells not transfected with an exogeno
the relative concentration of cellular tRNI
total cellular RNA. Assuming that apprc
cellular RNA is tRNA, we calculate that
cellular tRNA is tRNALYS. In cells transfe(
DNA and either wild-t'pe or mutant tRN
concentration of tRNA3ys increases to appr
of cellular tRNA. For cells transfected with
gene, this value includes both wild-type and s
since the 3' DNA probe does not distinguisl
tRNAs. These values are determined from
RNA extracted from a plate of cells, and t
Viral RNA average amount of tRNA3YS per microgram of total RNA
extracted from both transfected and nontransfected cells. Since
the majority of cells are not transfected, the increase in the
tRNALYs concentration in the transfected cells will clearly be
_?I..II 41 much higher than the average value indicates.
We have examined the effect of the increases in cellular
tRNALYS on the tRNALYS concentration in virus produced from
E D F the transfected cells. In Fig. 2 and 3, we show the relative
concentrations of tRNALYS and viral genomic RNA, respec-
tively, in the viral RNA samples, and we have used these data
to determine the number of tRNALYS molecules per two
molecules of genomic RNA (Table 1). There are eight mole-
cules of tRNA3LYs per two copies of viral genomic RNA in virus
produced from cells transfected with only the HIV-1 proviral
DNA, and this number doubles when cells are also transfected
with a gene for either wild-type or mutant tRNALYS, again
indicating that the mutant and wild-type tRNA molecules are
incorporated into the virus with equal efficiency. Using the
viral tRNA3YS/tRNALYs ratios determined by 2D-PAGE anal-
ysis (Fig. 1), we can also calculate the number of tRNAl1,2
molecules present in the virus. It is clear that the total number
of tRNALYS molecules per virus remains constant and that
increases in the amount of tRNA3YS incorporated into the virus
are accompanied by decreases in the number of molecules of
tRNA.1 packaged, with the total number of tRNALYS mole-
191 cules per virus remaining at 20. While the tRNA3LYs/tRNAlL2s
ratio is lower in virus containing suppressor tRNALYS than in
virus containing only wild-type tRNALYS, this change in ratio
is the result of very small differences in the actual concentra-
~CRwere performed tion of tRNALYS and tRNALys in the two viral types.
external standard) or We have determined the aminoacylation states of the cellu-
les used to measure lar and viral tRNA3Ys. The electrophoretic mobility of acylated
lucts were run on an tRNA in acid-urea PAGE has been reported to be slower than
lified products from that of the deacylated form, and this property can be used to
RNA RT-PCR stan- determine the degree of tRNA aminoacylation (11, 12, 31).
ied signals from in Figure 4 shows Northern (RNA) blots of cellular and viral
rd curve. Concentra- RNA samples electrophoresed in acid-urea gels, blotted ontopies were calculated Hybond N filter paper, and hybridized with radioactive
e.tRNAYS DNA probes. In Fig. 4A, cellular tRNA was hybrid-
ized with the probe complementary to the 3' 18-nucleotide
terminus of tRNALyS. Lanes 1, 3, and 5 represent cytoplasmic
cific DNA probe tRNA extracted from cells transfected with a plasmid contain-
otides of tRNA3Ys ing HIV-1 proviral DNA and either the wild-type tRNA3YS
1. The microgram gene (lane 1), the mutant suppressor tRNALYS gene (lane
nd C) were deter- 3), or no tRNA3Ys gene (lane 5). Lanes 2, 4, and 6 repre-
?le solutions. The sent the corresponding RNA samples which have been deacy-
d viral samples (D, lated in vitro. In cells either transfected with the wild-
s shown in Fig. 3. type tRNA3YS gene or not transfected with any tRNA gene, the
tRNA3YS and does tRNA3YS detected is entirely in the aminoacylated form. On
pressor tRNALYS. the other hand, less than 40% of the mutant suppressor
mined the relative tRNA3YS is aminoacylated. These gels also show variable
of transfected cells amounts of hybridizable RNA smaller than tRNA. This mate-
and these results rial is most likely degraded tRNALYS, which is greatest in cells
transfected with the suppressor tRNALYS gene, less abundant
,us tRNA3YS gene, in cells transfected with the wild-type tRNALYS gene, and not
k3YS is 2 ng/,lg of detected at all in cells not containing an exogenous tRNA
ximately 10% of gene. The slightly lower number of suppressor tRNALYS mol-
about 2% of the ecules found incorporated into virus could reflect the fact that
cted with proviral more of this tRNA than wild-type tRNA is found in a degraded
[A3YS, the relative form.
*oximately 6 ng/,ug The tRNA3Ys isolated from cells transfected with the HIV-1
the mutant tRNA proviral DNA and the suppressor tRNA3YS gene contains both
;uppressor tRNAs, wild-type endogenous tRNALYS and suppressor tRNA3YS, and
h between the two both types of tRNA will give a signal when hybridized with the
measurements of probe complementary to the 3' terminus of tRNALYS, which
they represent the was used for Fig. 4A. A DNA probe complementary to the
J. VIROL.
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FIG. 4. Electrophoretic detection of acylated and deacylated
tRNA3Y3. Cellular or viral RNA was isolated and electrophoresed
under acidic conditions as described in the text. The RNA was
electroblotted onto Hybond N and probed with wild-type or mutant
tRNA3'Y probes. (A) Ten-microgram samples of cellular RNA were
hybridized with the DNA oligomer complementary to the 3' 18
nucleotides of both wild-type and mutant tRNA33". RNA samples were
obtained from COS cells transfected with the following DNAs:
SVC21.BHlOLys3 (lanes 1 and 2), SVC21.BH10Su+ (lanes 3 and 4),
and SVC21.BH10 (lanes 5 and 6). Lanes 2, 4, and 6 contain RNA
samples which have been completely deacylated in vitro. (B) Cellular
RNA hybridized with the DNA oligomer complementary to the
anticodon arm of suppressor tRNA13Y. RNA samples were obtained
from COS cells transfected with the following DNAs: SVC21.BH
lOSu+ (lanes 7 and 10) (lane 7 contains RNA which has been
completely deacylated in vitro), SVC21.BH10 (lane 8), and SVC
21.BH1OLys (lane 9). (C) One microgram of either cellular or viral
RNA was hybridized with the DNA oligomer complementary to the 3'
18 nucleotides of both wild-type and mutant tRNA3LY. Lanes 11 and
15, COS-7 cellular RNA. Lane 11 contains RNA which has been
completely deacylated in vitro. Lanes 12 to 14 contain viral RNA
isolated from HIV-1 produced in the following cells: chronically
infected H9 (lane 12), chronically infected LTR(-) (lane 13), and
COS-7 cells transfected with SVC21.BH10 (lane 14).
suppressor tRNA anticodon arm was used to measure the
fraction of mutant suppressor tRNA aminoacylated. The spec-
ificity of this probe is shown in Fig. 5. The letters identify RNA
samples as designated in Fig. 1. In Fig. 5, the blots in lanes 1
and 2 were hybridized with probes complementary to either
the 3' terminus of tRNALYS (lane I) or the anticodon arm of
the suppressor tRNA (lane II). It can be seen in Fig. 5 that the
latter probe hybridizes only to tRNA extracted from either
I II
A
*B
C *
D
E
F
FIG. 5. Hybridization of RNA dot blots with DNA probes specific
for tRNAys or suppressor tRNA3Y. With the samples analyzed for
Fig. 2 to 4, 1 ,ug of the cellular RNA (A to C) and 1 ,ul of the viral RNA
(D to F) samples analyzed were hybridized either with the 3' DNA
probe specific for both wild-type and suppressor tRNAV' (I) or with
the anticodon arm probe specific for suppressor tRNA3Lr (LI).
.1000000
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FIG. 6. Viral infectivity. The time course of virus production in
MT-4 cells infected with virus produced from COS-7 cells transfected
with different plasmids is shown. Virus production was assessed by
measurement of RT activity in aliquots of clarified culture superna-
tants, as described in the text. Symbols for transfecting plasmid used:
l, SVC21.BH10; O, SVC21.BH1OLys3; 0, SVC21.BH10Su+.
cells transfected with the suppressor tRNA3L" gene or the virus
made in these cells. This not only shows the specificity of this
probe but also gives direct proof of the presence of the
suppressor tRNA3Ys in the virus.
In Fig. 4B, various cellular tRNA samples were hybridized
with this anticodon probe. Cells were transfected with a
plasmid containing the HIV-1 proviral DNA and either the
suppressor tRNA3YS (lanes 7 and 10), no tRNA gene (lane 8),
or the wild-type tRNA33"Y gene (lane 9). The tRNA in lane 7
has been deacylated in vitro. Only suppressor tRNA3YS gives a
signal, and Phosphor-imaging of lane 10 indicates that 64% of
the suppressor tRNA3LY is in the deacylated form.
Figure 4C shows the acylation state of tRNA3YS incorpo-
rated into the virus. tRNA samples were electroblotted onto
Hybond N paper and hybridized with the 3' probe. Lanes 11
and 15 represent deacylated (in vitro) and acylated (in vivo)
tRNAs, respectively, isolated from cells transfected with
HIV-1 proviral DNA and the wild-type tRNA3YS gene. Lanes
12, 13, and 14 represent viral RNA samples isolated from
HIV-1 produced in H9 cells (lane 12), LTR(-) cells (lane 13),
and COS-7 cells (lane 14). All viral tRNA3Ys is in the deacy-
lated form.
We have also examined the ability of the viral particles
produced from COS-7 cells transfected with the three different
types of plasmids to infect MT-4 cells. Figure 6 shows the viral
RT activity in 50-iil aliquots of cell culture medium removed at
days 1, 4, and 7. Cultures were replenished with fresh medium
after sampling at day 4. These results are the average values
from two separate experiments and indicate that there is no
difference in the abilities of these different viruses to infect
MT-4 cells. The decrease in virus production occurring be-
tween days 4 and 7 reflect the lysis of infected MT-4 cells,
which occurs during this time (3, 25).
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DISCUSSION
In this work, we show that the content of tRNA3YS in HIV-1
can be altered by altering the relative concentration of
tRNA3Ys in the cytoplasm. Because only a small fraction of
cells in tissue culture are transfected with the tRNALYS gene,
we can only estimate the changes in the concentration of
tRNALYS in transfected cells. The 3-fold increase in nanograms
of tRNA3YS per microgram of cellular RNA was determined
for a whole plate of cells, and it is likely that the relative
concentration of tRNA3Ys in the transfected cells may increase
10- to 20-fold.
In the virus produced by these cells, the number of tRNALYS
molecules incorporated doubles from 8 to 17 molecules per
virion, assuming 2 molecules of genomic RNA per virion. This
results in a decrease in the number of tRNA1LY molecules from
12 to 3 molecules per virion; i.e., the total amount of tRNALYS
per virus remains constant at 20. Similar results are found
when COS cells are transfected with the mutant tRNA3YS gene.
In another, similar set of experiments, we found that the
transfection of COS cells with wild-te or mutant tRNALYS
genes resulted in the number of tRNA3ys molecules per virion
increasing from 8 to 18 or 17, respectively, while the total
number of molecules of tRNALYS per virion remained at 20.
Virus containing an excess of wild-type or mutant tRNALYS
infects MT-4 cells with the same efficiency as wild-type virus.
The decrease in viral tRNA1 2sdoes not appear to affect viral
infectivity, perhaps because this tRNA plays no role in this
process or perhaps because the reduced number of molecules
is still sufficient to support a function of tRNALys in viral
replication. It would be of interest to decrease the viral content
of tRNA3LYs through the production of excess tRNALys in the
cell and to determine the effect of this on viral infectivity. This
work is in progress.
The number of tRNALYS molecules incorporated into the
virus is constant, and it could be limited by the space within the
virus. However, 40% of the viral tRNA population appears to
be non-tRNALys without any known function and probably
represents the random incorporation of small amounts of
cytoplasmic tRNAs (33). Excess cytoplasmic tRNALYS mole-
cules should be able to increase the viral tRNALYS number
beyond 20 by displacing these other tRNAs, but this does not
occur. Alternatively, the limited number of tRNALYS molecules
present in the virus may reflect the limited number of
Pr160gagY9P molecules incorporated into the virus. PM6069agP°
is the viral protein likely to carry the tRNALYS into HIV-1 (19).
This protein, which is not processed until after viral budding
(6, 35), contains the sequences for RT, a protein known to
interact with tRNA3YS in vitro (1, 2, 26, 36), and mutations
reducing or eliminating RT activity abolish select primer tRNA
incorporation in avian (22) and murine (18) viruses and in HIV
(19). However, if RT sequences within Prl6QrargPo do interact
with cytoplasmic tRNA3Ys, they may do so in a manner
different from the interaction occurring between mature p66/
p51 RT and tRNALYS. In vitro studies indicate that the
anticodon arm of tRNA3YS is involved in the interaction
between mature RT and tRNA3YS (1, 2, 26, 36), yet tRNAL2s,
which differs in this region from tRNALYS by 6 of 17 bases, is
incorporated into the virus with the same efficiency as
tRNALYS. Furthermore, as shown in this work, altered se-
quence in the anticodon loop does not appear to diminish the
ability of the mutant tRNALYS to be incorporated into the virus.
It therefore seems unlikely that this region of the tRNA is
involved in the select interaction which occurs between
tRNALYs and Prl6Orar9I° during packaging.
In the mutant suppressor tRNA3'YS, the modified base mcm5s2
U, which is found in wild-type tRNA3YS at the first position in the
anticodon (position 34), has been replaced with C. This does not
seem to affect the ability of the tRNA to be packaged into the
virus. On the other hand, this mutant tRNA may not be placed
on the HIV-1 genome as efficiently as wild-type tRNAALYS. It
has been reported that the anticodon loop of tRNA3YS inter-
acts with an A-rich region upstream of the HIV-1 primer-
binding site and that dethiolation of the modified nucleotide at
position 34 destabilizes this interaction (13). Virus containing
suppressor tRNALYS appears to be as infective as wild-type
virus, and this may be because the mutant tRNALYS is not an
effective competitor with wild-type tRNA3YS for binding to the
genomic RNA. Because the anticodon DNA probe specific for
suppressor tRNA3YS hybridizes much more weakly than the
DNA probe hybridizing to the 3' termini of both wild-type and
suppressor tRNALYS, we have been unable to specifically detect
the extent of binding of the suppressor tRNA3YS to the viral
RNA genome.
Does tRNALYS enter the virus in the acylated or deacylated
form? It is clear that in the infected cell, all detectable
cytoplasmic tRNA3YS is acylated. The tRNA3LYS in the virus is
deacylated, but we do not know if this is the state of the viral
tRNA in vivo or is due to a spontaneous tRNA deacylation
induced by the virus remaining for many hours in culture
medium at neutral pH. Nevertheless, the deacylation of viral
tRNALYS is expected as a requirement for this molecule to
function as a primer tRNA for RT. Does deacylation occur in
the cytoplasm or in the virus? In the cytoplasm, deacylation of
tRNA occurs during translation, and it may be that the
cytoplasmic source of viral tRNALYS is tRNALYS which has just
left the P site on the ribosome and which interacts with a
growing Pr1600Qar"Po protein still bound to the ribosome. Our
data indicate that inhibiting aminoacylation of tRNALYS by
greater than 60% does not affect incorporation of the tRNA
into the virus. However, we are not yet able to determine
whether the acylated or deacylated form of the mutant sup-
pressor tRNA is more efficient in entering the virus, and
resolution of this question may require studies with a mutant
tRNA unable to be acylated in vivo.
The transient expression of tRNA3YS in our system cannot
accurately measure the effect of excess tRNALYS on host cell
viability. However, Ho and colleagues (11, 12) created stable
CHO cell lines which contained approximately 250 stably
integrated human tRNA3YS genes, coding for either the wild-
type tRNA3YS or the amber suppressor tRNA3YS used in this
work. These cells contained approximately 50-fold more
tRNALYS than found in normal cells. As reported here for
virus-infected COS-7 cells, they also found that all wild-type
tRNALYs was aminoacylated, while the suppressor tRNA3YS
was only 30 to 50% aminoacylated. The cellular concentrations
of tRNAs, relative to each other, mirror the relative concen-
trations of the major codons used (8), and this has been
interpreted as a way the cell minimizes the time for placement
of the correct tRNA at the most commonly used codons (30).
A 50-fold increase in tRNALYS, which normally represents 2%
of the total tRNA, would halve the cellular concentration of all
other tRNAs, and apparently this does not diminish cell
viability.
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